Back |
home / stock / ktta / ktta message board
Subject | By | Source | When |
---|---|---|---|
Today I learned that Premium means under the | KOmani | investorshub | 11/24/2021 2:01:31 PM |
Well that just smoked me | Tiger Money | investorshub | 11/24/2021 1:55:46 PM |
$KTTA $30m offering at 3.50/share with warrants at 3.50 | TheFinalCD | investorshub | 11/24/2021 1:54:20 PM |
15 min before PM @ 7.34 | reena969 | investorshub | 11/24/2021 11:47:22 AM |
PM in 30 min KTTA is @ 8.50 | reena969 | investorshub | 11/24/2021 11:34:56 AM |
$KTTA - Tuesday Rundown, Wednesday Expectations | Jake L | investorshub | 11/24/2021 6:56:15 AM |
Shorts haven't covered, I'm looking for them to | reena969 | investorshub | 11/24/2021 5:08:28 AM |
I did not jump back in, slowly learning | Fluffy100 | investorshub | 11/23/2021 10:04:50 PM |
If you made some money on the flip, | bcapps66 | investorshub | 11/23/2021 9:51:59 PM |
In like Flynn | Tiger Money | investorshub | 11/23/2021 8:50:40 PM |
Where did all the shares come from? | Fluffy100 | investorshub | 11/23/2021 7:23:22 PM |
Got to love the shorts who just thumb | KOmani | investorshub | 11/23/2021 4:27:33 PM |
Reset | Tiger Money | investorshub | 11/23/2021 4:12:01 PM |
Well, the stock is hitting high $7 and | KOmani | investorshub | 11/23/2021 3:53:17 PM |
bought 2.45 sold 4.05 premarket. dont rub it in. | alchemytrader | investorshub | 11/23/2021 3:25:35 PM |
News, Short Squeeze, Breakout and More Instantly...
Pasithea Therapeutics Corp. Company Name:
KTTA Stock Symbol:
NASDAQ Market:
Pasithea Therapeutics Corp. Website:
MIAMI, June 13, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis typ...
-- PAS-004 inhibition of in vitro NRAS cell lines does not plateau in contrast to approved MEK inhibitors -- -- PAS-004 inhibition of in vitro NRAS cell lines is greater than selumetinib and binimetinib and similar to trametinib -- -- PAS-004 shows superior activity versus selumetinib and...